for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Guardant Health Inc

GH.OQ

Latest Trade

77.58USD

Change

-1.22(-1.55%)

Volume

432,424

Today's Range

74.52

 - 

78.97

52 Week Range

74.52

 - 

181.07

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
78.80
Open
78.38
Volume
432,424
3M AVG Volume
23.03
Today's High
78.97
Today's Low
74.52
52 Week High
181.07
52 Week Low
74.52
Shares Out (MIL)
101.66
Market Cap (MIL)
7,886.50
Forward P/E
-17.82
Dividend (Yield %)
--

Next Event

Q4 2021 Guardant Health Inc Earnings Release

Latest Developments

More

Guardant Health And Foundation Medicine Reach Settlement In Digital Sequencing Technology Litigation

Guardant Health Reaches Target Enrollment Of 12,750 Patients In ECLIPSE Pivotal Study For Its LUNAR™-2 Blood Test To Detect Colorectal Cancer

Guardant Health Reports Q3 NON-GAAP Loss Per Share Of $0.70

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Guardant Health Inc

Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer through use of its blood-based tests, data sets and advanced analytics. It has developed its Guardant360, Guardant360 CDx and GuardantOMNI liquid biopsy-based tests for advanced stage cancer. It also developed its Guardant Reveal liquid biopsy-based test for residual and recurring cancer to address the need in Stage II-III colorectal cancer. Its Guardant360 test is a molecular diagnostic test measuring 74 cancer-related genes. Its Guardant360 CDx test is a liquid biopsy test measuring 55 cancer related genes. Its GuardantOMNI test has a broader 500-gene panel, all of which analyze circulating tumor Deoxyribonucleic Acid (DNA) in blood. The Company's tests are used by biopharmaceutical companies for a range of applications, including identifying target patient populations to accelerate translational science research and clinical trial enrollment, and companion diagnostic development.

Industry

Biotechnology & Drugs

Contact Info

505 Penobscot Dr

REDWOOD CITY, CA

94063-4737

United States

+1.650.2907575

http://www.guardanthealth.com

Executive Leadership

Helmy A. Eltoukhy

Chairman of the Board, Co-Chief Executive Officer

Amirali Talasaz

President, Co-Chief Executive Officer, Director

Michael Bell

Chief Financial Officer

John Gomes Saia

Senior Vice President, General Counsel, Corporate Secretary

Craig Eagle

Chief Medical Officer

Key Stats

1.60 mean rating - 15 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.1K

2019

0.2K

2020

0.3K

2021(E)

0.4K
EPS (USD)

2018

-2.800

2019

-0.840

2020

-2.600

2021(E)

-4.352
Price To Earnings (TTM)
--
Price To Sales (TTM)
22.94
Price To Book (MRQ)
11.11
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
159.87
LT Debt To Equity (MRQ)
159.87
Return on Investment (TTM)
-25.36
Return on Equity (TTM)
-23.25

Latest News

Latest News

BRIEF-Guardant Health Announces Collaboration With Janssen To Develop Liquid Biopsy Companion Diagnostic

* GUARDANT HEALTH ANNOUNCES COLLABORATION WITH JANSSEN TO DEVELOP LIQUID BIOPSY COMPANION DIAGNOSTIC

BRIEF-Guardant Health Launches Real-World Clinical-Genomic Platform To Accelerate Precision Oncology Drug Development

* GUARDANT HEALTH LAUNCHES REAL-WORLD CLINICAL-GENOMIC PLATFORM TO ACCELERATE PRECISION ONCOLOGY DRUG DEVELOPMENT Source text for Eikon: Further company coverage:

BRIEF-Guardant Health Appoints Vijaya Gadde To Board Of Directors

* GUARDANT HEALTH APPOINTS VIJAYA GADDE TO ITS BOARD OF DIRECTORS

BRIEF-Guardant Health Increased Number Of Directors On Board To Seven

* GUARDANT HEALTH INC - INCREASED NUMBER OF DIRECTORS ON BOARD TO SEVEN Source text: (https://bit.ly/3e9BFCH) Further company coverage:

BRIEF-Guardant Health Announces Pricing Of Upsized Public Offering

* GUARDANT HEALTH ANNOUNCES PRICING OF UPSIZED PUBLIC OFFERING

BRIEF-Guardant Health Announces Proposed Public Offering Of Common Stock

* GUARDANT HEALTH ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Guardant Health Posts Quarterly Loss Per Share Of $0.27

* GUARDANT HEALTH REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES FULL YEAR 2020 OUTLOOK

SoftBank's Vision Fund to borrow $4 billion against stakes in Uber and two others: FT

SoftBank's Vision Fund is looking to borrow $4 billion against its stakes in Uber Technologies Inc, soon-to-go-public Slack Technologies Inc, and blood-testing company Guardant Health Inc, the Financial Times reported, citing people directly involved in the deal.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up